Enhertu Gets US FDA’s Orphan Status for Gastric Cancer

May 25, 2020
Daiichi Sankyo and partner AstraZeneca said on May 22 that their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) received orphan drug designation in the US for the treatment of gastric cancer including gastroesophageal junction cancer. In the US, the drug...read more